ENvue Medical Appoints Industry Veteran Marc Waldman as Vice President, Commercial
Rhea-AI Summary
ENvue Medical (NASDAQ: FEED; NASDAQ: NAOV) announced on January 21, 2026 the appointment of Marc Waldman as Vice President, Commercial to lead U.S. commercialization. Waldman brings 35+ years of medical device commercial leadership, GPO and IDN experience, and sector expertise in patient safety, enteral feeding and neonatal nutrition. He previously grew a neonatal enteral portfolio from $39M to $70M in 3.5 years and will focus on expanding ENvue’s current presence in 38 hospitals and accelerating revenue across the company’s enteral platform.
Positive
- 35+ years of commercial leadership experience
- Led revenue growth from $39M to $70M in 3.5 years
Negative
- Current commercial footprint limited to 38 hospitals
News Market Reaction
On the day this news was published, FEED gained 2.44%, reflecting a moderate positive market reaction. Argus tracked a peak move of +23.6% during that session. Argus tracked a trough of -25.7% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $33K to the company's valuation, bringing the market cap to $1M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
No peer stocks with momentum or same-day headlines were provided, so the -6.11% move appears stock-specific rather than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 14 | Product launch | Positive | -26.7% | OTC ENFit syringes launch for enteral feeding and medication delivery. |
| Jan 09 | Clinical program | Positive | -7.6% | Exploratory program using NanoVibronix tech for NG tube pain reduction. |
| Jan 08 | Corporate visibility | Positive | +11.1% | Nasdaq Opening Bell ceremony showcasing non-invasive enteral technologies. |
| Dec 15 | Leadership change | Positive | -5.6% | Appointment of David Johnson as Chairman and growth plans for 2026. |
Over the last four news events, the stock showed 3 divergences and 1 alignment, often selling off on seemingly positive announcements.
Recent news for ENvue Medical shows a string of operational updates and visibility events. On Dec 15, 2025, the company named David Johnson as Chairman while highlighting its 510(k)-cleared feeding-tube system in 38 US hospitals. Early January 2026 brought a Nasdaq Opening Bell ceremony and launch of an exploratory program using NanoVibronix vibration technology. On Jan 14, 2026, ENFit syringes were launched over the counter. Today’s appointment of a commercial leader fits this pattern of building out commercialization and leadership around its enteral care platform.
Market Pulse Summary
This announcement highlights ENvue’s focus on execution by adding a commercial leader with over 35 years of medical device experience and a record of growing revenue from $39M to $70M. It follows recent product, program, and leadership updates that aimed to build its enteral care platform and expand beyond the current 38-hospital base. Investors may watch for concrete adoption metrics, revenue trends, and further commercialization milestones to assess the impact of this leadership change.
Key Terms
enteral care medical
enteral feeding medical
neonatal nutrition medical
AI-generated analysis. Not financial advice.
Marc Waldman brings over 35 years of commercial leadership experience in the medical device industry with a proven track record of driving top-line growth
TYLER, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) (NASDAQ: NAOV) (“ENvue,” “ENvue Medical” or the “Company”), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced the appointment of Marc Waldman as Vice President, Commercial. In this role, Mr. Waldman will lead ENvue’s U.S. commercialization strategy, with a focus on expanding its existing presence in 38 hospitals and accelerating revenue across the Company’s enteral platform.
“Marc is a highly accomplished sales leader with extensive GPO and IDN expertise and long-standing relationships throughout U.S. hospitals. Combined with his deep knowledge across patient safety, enteral feeding, and neonatal nutrition, we are confident in his ability to drive our U.S. commercial execution efforts forward,” said Doron Besser, MD, CEO of ENvue Medical. “Marc brings a steady, execution-based leadership style that we believe aligns with our mission and growth objectives, and we look forward to scaling this business together.”
“This is an incredibly exciting time to join ENvue, and I’m honored to have the opportunity to work alongside such a dedicated and passionate team,” said Marc Waldman, VP, Commercial of ENvue Medical. “Their focus on implementing non-invasive technology and solutions to better the lives of patients is truly inspiring, and I look forward to contributing to this important work as we grow and expand our reach.”
Mr. Waldman has over 35 years of experience in the medical device industry, including nearly a decade with NeoMed and, following its acquisition, with Avanos Medical, where he served as North America Sales Director for the neonatal enteral feeding portfolio. He led strategic planning, supply-recovery initiatives, and expanded key accounts. During his role as North America Sales Director, he led a national team and grew revenue from approximately
About ENvue Medical, Inc.
ENvue Medical, Inc. (NASDAQ: FEED) is a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings. Headquartered in Tyler, Texas, with research and development in Tel-Aviv and Nesher, Israel, the Company focuses on two distinct technology platforms:
- ENvue™ Navigation Platform, developed and operated by ENvue Medical Inc., with offices in Arlington Heights, Illinois, and Tel-Aviv, Israel, is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. FDA 510(k) cleared for adult use, ENvue provides real-time bedside visualization of tube movement and supports informed decision-making during the placement procedure. Future platform expansion may include pediatric and vascular access applications.
- ENvue Medical aims to advance standards in non-invasive therapy and minimally invasive navigation, with a commitment to patient safety, clinical usability, and technology innovation across a range of healthcare environments.
- Acoustic-based therapeutic technologies, including PainShield® and UroShield®, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms.
Forward-Looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. These forward-looking statements include, but are not limited to: statements regarding the adoption and implementation of ENvue Medical’s platforms, anticipated commercial expansion, growth, scalability, and implementation of ENvue Medical’s products, the success of ENvue’s programs, market interest in the Company’s technology, and future expectations for strategic growth. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: (i) market acceptance of the Company’s existing and new products; (ii) clinical performance and operational outcomes; (iii) delays or complications in product implementation; (iv) intense competition in the medical device industry; (v) product liability or performance issues; (vi) limitations in manufacturing or supply chain capabilities; (vii) reimbursement limitations; (viii) intellectual property protection; (ix) healthcare regulatory changes in the U.S. and abroad; and (x) the need for additional capital. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Investors and security holders are urged to read these documents free of charge at: www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.
Investor Contact:
KCSA Strategic Communications
Valter Pinto, Managing Director
PH: (212) 896-1254
envue@kcsa.com
Media Contact:
KCSA Strategic Communications
Raquel Cona, Vice President
PH: (516) 779-2630
envue@kcsa.com
FAQ
Who is Marc Waldman and what role did ENvue Medical appoint him to on January 21, 2026 (FEED)?
What commercial experience does Marc Waldman bring to ENvue Medical (FEED)?
How did Marc Waldman perform in prior roles according to ENvue’s announcement (FEED)?
What will Marc Waldman focus on at ENvue Medical (FEED)?
How large is ENvue’s current hospital presence that Waldman will expand (FEED)?
Does Marc Waldman hold any industry leadership roles relevant to enteral safety (FEED)?
